A new generation of high-content imaging systems such as the PerkinElmer Operetta CLS High Content Imaging System and Harmony High Content Imaging and Analysis Software are helping scientists to blaze new trails in cancer drug therapy.
Scientists at UCLA's David Geffen School of Medicine are working with bioluminescent, fluorescent, and positron emission tomography (PET) technologies to reduce infections in post-surgical orthopedic patients as well as fight against metabolic cancer.
PerkinElmer and University of Colorado scientists review the current state of high-content (3D) imaging technologies that are advancing rapidly in the biological and biochemical sectors.
Flat panel x-ray detectors have revolutionized not only medicine but manufacturing.
Researchers offer evidence of the importance of epithelial-to-mesenchymal transition (EMT) in the progression of chronic kidney disease.
PerkinElmer's Phenoptics™ quantitative pathology research system helped researchers reveal a predictive biomarker for Merkel cell carcinoma.
Using TIBCO Spotfire® visualization tools, PerkinElmer demonstrates this analytical versatile software in the study of infectious diseases.
PerkinElmer-GIS Centre for Precision Oncology leverages genome expertise and leading edge imaging instrumentation to develop new cancer therapies.
In a medical first, UNC researchers engineer and record skin cells becoming cancer killers using PerkinElmer’s IVIS system.
Monash Institute of Pharmaceutical Sciences is working to develop an inhaled oxytocin treatment for PPH, excessive bleeding after childbirth that kills an estimated 140,000 women a year.